News | December 16, 2025
Anova launches AI-powered patient matching platform to speed clinical trial enrollment
Clinical trial enrollment has long been a bottleneck in drug development
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Subscribe To Our Newsletter & Stay Updated
